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Introduction: Patients with non-small cell lung cancer (NSCLC)
require careful preoperative staging to define resectability for
potential cure. 18Fluorodeoxyglucose positron emission tomog-
raphy combined with computed tomography (18FDG PET-CT) is
widely used to stage NSCLC. If the mediastinum is positive on
PET-CT examination, some practitioners conclude that the pa-
tient is inoperable and refer the patient for nonsurgical treatment.
Methods: In this analysis of a previously reported trial comparing
PET-CT with conventional imaging in the diagnostic work-up of
patients with clinical stage I, II, or IIIA NSCLC, we determined the
accuracy of PET-CT in mediastinal staging compared with invasive
mediastinal staging either by mediastinoscopy alone or by medias-
tinoscopy combined with thoracotomy.
Results: All 149 patients had mediastinal nodal staging at medias-
tinoscopy alone (14), thoracotomy alone (64), or both (71). The
sensitivity of PET-CT was 70% (95% confidence interval [CI],
48–85%), and specificity was 94% (95% CI, 88–97%). Of 22
patients with a PET-CT interpreted as positive for mediastinal
nodes, 8 did not have tumor. The positive predictive value and
negative predictive value were 64% (95% CI, 43–80%) and 95%
(95% CI, 90–98%), respectively. Based on PET-CT alone, eight
patients would have been denied potentially curative surgery if the
mediastinal abnormalities detected by PET-CT had not been evalu-
ated with an invasive mediastinal procedure.
Conclusions: PET-CT assessment of the mediastinum is associated
with a clinically relevant false-positive result. Our study confirms
the need for pathologic confirmation of mediastinal lymph node
abnormalities detected by PET-CT.
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Lung cancer is the leading cause of cancer-related mortalityin North America. It was estimated that in 2010, approx-
imately 157,300 persons died of this disease in the United
States,1 with the corresponding number in Canada being
20,600.2 Non-small cell lung cancer (NSCLC) makes up 80%
of all lung cancers. Unfortunately, only 25% of patients will
have resectable disease at presentation. Of those with stage I
and II disease, 20 and 40%, respectively, will ultimately
relapse with metastatic disease that was occult at the time of
presentation.3 These statistics underscore the need for both more
precise staging and more effective stage-specific therapies.
In the absence of distant metastatic disease, the status
of the mediastinal lymph nodes determines the therapeutic
approach in NSCLC. Patients without mediastinal lymph
node involvement are considered candidates for potentially
curative surgical resection. In contrast, those with tumor in
the mediastinal lymph nodes are not candidates for primary
surgery and are offered other forms of therapy depending on
performance status and other clinical factors.4,5
Mediastinal staging includes both noninvasive tech-
niques such as computed tomography (CT), and invasive
methods such as mediastinoscopy, endobronchial ultrasound
with transbronchial needle aspiration, and endoscopic ultra-
sound fine needle aspiration. Although CT provides anatomic
information, it has poor sensitivity (approximately 50%) and
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specificity (approximately 85%) for detecting mediastinal
tumor.6 Mediastinoscopy, which has been considered the
reference standard for staging mediastinal lymph nodes, has a
false-negative rate (i.e. 1-negative predictive value [NPV]) of
approximately 10%.7
18Fluorodeoxyglucose positron emission tomography
(PET) is a functional imaging modality that can potentially
detect tumor activity in nonenlarged structures and allow
earlier detection of metastatic disease.8 Based on a number of
trials, PET-CT is now widely used for the staging of
NSCLC9–13 and offers some advantage over CT alone in
assessing the mediastinal nodes.14
The purpose of the current study was to determine the
accuracy of PET-CT in staging the mediastinum compared
with pathological staging based on observations made during
a previously reported randomized trial of conventional stag-
ing versus PET-based staging.13 Pathological staging was
determined surgically with mediastinoscopy, node sampling
at thoracotomy, or both.
PATIENTS AND METHODS
Population
The Early Lung PET trial (ELPET) randomized pa-
tients who had a chest CT scan and proven NSCLC to
conventional staging with bone scan, CT abdomen and brain
imaging, or PET-CT and brain imaging. Those patients who
were randomized to the PET-CT arm of the trial are the
subjects of this study. Details of the trial design and proce-
dures have been published previously.13 Eligible patients had
histologically or cytologically proven NSCLC; clinical stage
I, II, or IIIA disease based on CT chest; and were considered
candidates for surgical resection. Staging was based on the
6th edition of the American Joint Committee on Cancer
(AJCC)/Union Internationale Contre le Cancer (UICC) Tu-
mor, Node, Metastasis Staging Manual. Consenting patients
from four academic metropolitan tertiary centers and four
community hospitals in Ontario, Canada, were enrolled into
ELPET between 2004 and 2007.
This study was supported through grants from the
Ontario Ministry of Health and Long-Term Care and the
Canadian Institutes of Health Research and was coordinated
by the Ontario Clinical Oncology Group. The study protocol
was approved by the local Institutional Review Board at each
clinical center.
Imaging
All patients had a CT scan of the chest before study
entry. Patients who were randomized to PET staging under-
went whole body 18fluorodeoxyglucose PET-CT and cranial
imaging using either CT or magnetic resonance imaging.
Details of imaging procedures have been published previ-
ously.13
Interpretation of all PET-CT images occurred at the
locations where the PET study was done. A 5-point ordinal
scale was used to record the interpreter’s degree of suspicion
for an abnormality. This scale consisted of the following
categories: 0, normal; 1, probably normal; 2, equivocal; 3,
probably abnormal; and 4, definitely abnormal.15 The stan-
dardized uptake value was determined and was used to aid in
grading the identified abnormalities. A specific cutoff uptake
value for the determination of the presence or absence of
cancer was not provided to readers of the scans. If the
PET-CT or CT suggested the presence of metastatic disease,
confirmation by biopsy or further diagnostic imaging modal-
ities was required.
Invasive Mediastinal Staging
In patients whose PET-CT was negative for mediastinal
disease, surgeons had the option of performing cervical
mediastinoscopy, anterior mediastinotomy, or both, or pro-
ceeding directly to thoracotomy. If mediastinoscopy was
performed, it was recommended that stations 2 R/L, 4 R/L,
and 7 should be explored and nodes sampled if present.
Because of the 10% false-negative rate (1-NPV) for
mediastinoscopy, all patients were required by protocol to
have detailed lymph node sampling at thoracotomy even if
they had mediastinal node sampling by mediastinoscopy.7 On
the right side, this consisted of removing one or two lymph
nodes, if present, from each of the following lymph node
stations: 2R (upper paratracheal), 4R (lower paratracheal), 7
(subcarinal), and 10R (tracheobronchial angle). For left-sided
tumors, sampling consisted of removing one or two lymph
nodes from each of station 2L (upper paratracheal), 4L (lower
paratracheal), station 5 (aortopulmonary window), 6 (para-
aortic anterior mediastinal), 7 (subcarinal), and 10L (tracheo-
bronchial angle), if present. Any other suspicious nodes were
sampled. However, all protocol-specified lymph node stations
sampled at mediastinoscopy were resampled at thoracotomy.
If a CT of the chest or the PET-CT demonstrated
suspicious mediastinal adenopathy based on either size crite-
ria (1 cm) or increased uptake on PET-CT, mediastinos-
copy was required before proceeding to thoracotomy. Pa-
tients with proven N2- or N3-positive stage IIIA/B disease on
mediastinoscopy were declined thoracotomy and received
stage-appropriate therapy. If mediastinoscopy was negative,
patients underwent thoracotomy and resampling of mediasti-
nal nodes as per the protocol outlined above.
Surgery
Anatomic lobectomy or pneumonectomy was per-
formed for stage I and II disease, as appropriate, by a
posterolateral thoracotomy or video-assisted thoracotomy.
Patients with stage IIIA disease were resected after neoadju-
vant therapy if deemed resectable by the treating surgeon.
Adjuvant therapy (stage II or IIIA) was permitted.
Study Outcomes
The primary goal of this study was the estimation of the
diagnostic accuracy parameters: sensitivity, specificity, posi-
tive predictive value (PPV), and negative predictive value
(NPV) of PET-CT in staging the mediastinum in comparison
with the reference standard of pathology by surgical staging
with node sampling by mediastinoscopy or thoracotomy or
both (in this case, the worst result was used). A secondary
outcome was the estimation of test characteristics of PET-CT
in comparison with pathologic staging by mediastinoscopy
only as the reference standard.
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Statistical Considerations
For the purpose of the primary analysis, it was decided
a priori to distinguish between N0/N1 and N2/N3 nodes, as
the former group would be candidates for surgical manage-
ment, whereas the latter group would generally not be man-
aged surgically.5
The gold standard for the calculation of the test char-
acteristics (sensitivity, specificity, PPV, and NPV) was the
presence (or absence) of tumor in lymph nodes sampled at
mediastinoscopy and/or thoracotomy. The confidence inter-
vals (CIs) for the estimates of the diagnostic accuracy param-
eters were obtained using the Wilson Score method for single
proportions.
RESULTS
Between June 2004 and August 2007, 589 patients
were assessed for eligibility, of whom 380 met the eligibility
criteria of the study and were approached for consent. Of
these, 337 agreed to participate and 170 were randomized to
the PET-CT arm. One subject refused study investigations
after randomization and was, therefore, excluded.
Of the 114 patients with a negative PET-CT, 58 (51%)
had a mediastinoscopy attempted. This compares to 27 (77%)
of 35 patients with a positive PET-CT, p  0.006.
Mediastinoscopy was performed in 85 patients in the
PET-CT arm (and in one of these patients, nodal sampling
was unsuccessful because of the presence of calcified plaque
in the innominate artery). In 12 patients, mediastinoscopy
was positive for N2 or N3 disease. The remaining 73 patients
went on to thoracotomy with nodal sampling. However, two
patients did not undergo nodal sampling at thoracotomy. Of
the 84 patients who did not have mediastinoscopy, 19 did not
undergo thoracotomy: 17 upstaged with metastases, one with
rectal cancer detected by PET, and one who refused invasive
treatment. Sixty-five patients had thoracotomy, and one of
them did not have node sampling because the tumor was
unresectable at thoracotomy. In total, 149 patients had medi-
astinal node sampling at mediastinoscopy or thoracotomy or
both (Figure 1). The baseline characteristics of the population
that underwent mediastinal nodal sampling either at medias-
tinoscopy or thoracotomy are presented in Table 1.
Using mediastinoscopy and/or thoracotomy as the ref-
erence standard, PET-CT detected disease in 14 of 20 patients
with pathologically proven N2/N3 disease. The scan was
negative in 121 of 129 patients who did not have N2/N3
disease on pathology (Table 2). Hence, the sensitivity of
PET-CT was 70% (95% CI, 48–85%) and specificity was
94% (95% CI, 88–97%). Of the 22 patients with a positive
FIGURE 1. Study flow diagram. PET-CT, positron emission
tomography combined with computed tomography.
TABLE 1. Baseline Characteristics of Analyzable PET-CT
Patients
Characteristic
PET-CT,
n  149
Age (yr), median (minimum to maximum) 67 (41–86)
Gender, n (%)
Female 73 (49)
Male 76 (51)
Smoking, n (%)
Never 9 (6)
Ex-smoker 99 (66)
Current smoker 41 (28)
ECOG performance status, n (%)
0 91 (61)
1 55 (37)
2 3 (2)
Primary tumor size (cm), median (minimum to maximum) 3.1 (0.8–8.7)
Tumor location—right, n (%) 90 (60)
Clinical stage, n (%)
IA 78 (52)
IB 41 (28)
IIA 5 (3)
IIB 11 (7)
IIIAa 14 (9)
Histological/cytological diagnosis, n (%)
Adenocarcinoma 64 (43)
Squamous 24 (16)
Large cell 5 (3)
NSCLC 53 (36)
Suspicious for NSCLC 3 (2)
a Includes one IIIB patient who was T4N0M0 at baseline but assessed as
resectable.
PET-CT, positron emission tomography and computed tomography; ECOG, East-
ern Cooperative Oncology Group; NSCLC, non-small cell lung cancer.
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PET-CT in N2 and N3 nodes, 8 did not have tumor in
mediastinal nodes on invasive staging. Of the four patients
whose PET-CT was positive in N3 nodes, only one was
positive on invasive staging. The PPV and NPV were 64%
(95% CI, 43–80%) and 95% (95% CI, 90–98%), respectively
(Table 3). In the eight patients with a false-positive PET-CT
result, no underlying conditions (e.g., granulomatous disease,
active infection, or inflammation) were identified. Further-
more, although pathology reported associated findings in the
lymph nodes of four patients (e.g., anthracosis, histiocytosis,
adhesions, and lymphoid hyperplasia), no consistent patterns
were identifiable to explain the false-positivity.
Separate analysis by clinical stage determined by CT
scan (clinical stages IA and IB versus IIA, IIB, and IIIA) was
performed (Table 3). The sensitivity and PPV for clinical
stages II and IIIA were larger than they were for stage I,
whereas the specificity and NPV were lower for the higher
stages. Similarly, separate analysis by clinical nodal stage
determined by CT scan is listed in Table 4.
At mediastinoscopy, the four most common nodal sta-
tions biopsied were 2R, 4R, 4L, and 7. The corresponding
proportions of patients who had these stations biopsied were
47.6, 86.9, 56.0, and 77.4%. Using only mediastinoscopy as
the reference standard, 12 patients were noted to have N2 or
N3 disease, and all of these were found to be positive by
PET-CT. However, of the 21 patients identified as having N2
or N3 disease by PET-CT, 9 patients were determined to be
N0 by mediastinoscopy (Table 5). The accuracy estimates for
the comparison of PET-CT versus mediastinoscopy alone
were sensitivity 100% (95% CI, 76–100%); specificity 88%
(95% CI, 78–93%); PPV 57% (95% CI, 37–76%); and NPV
100% (95% CI, 94–100%).
DISCUSSION
The determination of mediastinal lymph node status is
an essential part of staging NSCLC. Medically fit patients
will be offered potentially curative surgery if mediastinal
nodes are not involved. If mediastinal lymph nodes are
involved by tumor, primary surgery is not recommended and
such patients are commonly treated with radiation therapy
with or without chemotherapy or supportive care alone,
depending on performance status and other clinical factors. In
highly selected patients with N2 disease, surgery may be part
of multimodality therapy. Imaging with PET-CT is now
widely used for the staging of NSCLC.12,13,16
In our study, the sensitivity and PPV of PET-CT when
compared with the composite reference standard of medi-
astinoscopy and thoracotomy were 70 and 64%, respec-
tively. These results highlight the issue of false-negative
test results, which may result from a small volume of
metastatic disease being present or relatively low meta-
bolic activity or both. A wide range of sensitivities for
PET-CT have been reported in the literature.17–22 There are
limitations in comparing sensitivities and other accuracy
parameters between studies because the studies may differ
in the prevalence of malignancies, size of nodes, tumor
histology, study size, and standardized uptake value
used.17–22
In our study, the specificity and NPV of PET-CT were
over 90%, which is similar to results reported by others.18,19
In the group that tested positive with PET-CT, the percentage
of false-positives (i.e., 1-PPV) was 36%. The corresponding
data for the studies reported by Lee,19 Hwangbo,17 and
Sanli18 were 44, 62, and 44 %, respectively. Conditions such
as granulomatous inflammation may cause enlarged nodes.
The prevalence of tuberculosis, or histoplasmosis may in-
crease the rate of false-positive PET-CT. However, we were
unable to explain the false-positive imaging in our patients.
In our study, we did not assess the size of the nodes. In
other studies in NSCLC, centrally located tumors have been
found to be significantly associated with occult N2 disease.
We did not assess the location of tumors. Our evaluation of
the diagnostic accuracy of PET-CT by lymph node station
was limited by the small number of nodes examined by
station (data not reported).
TABLE 2. Comparison of PET-CT and the Composite
Reference Standard
PET-CT
Composite Reference Standard Mediastinoscopy and
Thoracotomy
N0 N1 N2 N3 Total
N0 101 11 2 0 114
N1 1 8 4 0 13
N2 7 0 10 1 18
N3 1 0 2 1 4
Total 110 19 18 2 149
N0  N1 N2  N3
N0  N1 121 6 127
N2  N3 8 14 22
Total 129 20 149
PET-CT, positron emission tomography and computed tomography; N, node.
TABLE 3. Sensitivity, Specificity, Positive Predictive Value, and Negative Predictive Value by Clinical Stage at Baseline
Clinical Stage
Sensitivity (%) Specificity (%) PPV (%) NPV (%)
Estimate 95% CI Estimate 95% CI Estimate 95% CI Estimate 95% CI
IA, IB 57 (4/7) 25–84 96 (108/112) 91–99 50 (4/8) 22–78 97 (108/111) 92–99
IIA, IIB, IIIAa 77 (10/13) 50–92 76 (13/17) 53–90 71 (10/14) 45–88 81 (13/16) 57–93
All subjects 70 (14/20) 48–85 94 (121/129) 88–97 64 (14/22) 43–80 95 (121/127) 90–98
a Includes one IIIB patient who was T4N0M0 at baseline but assessed as resectable.
PPV, positive predictive value; NPV, negative predictive value; CI, confidence interval.
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Although mediastinoscopy improves the accuracy of
preresection staging,23 it is invasive, requires general anes-
thesia, and may be falsely negative.7 We chose to compare
PET-CT with mediastinoscopy because some surgeons do not
resample mediastinal nodes at the time of thoracotomy if a
previous mediastinoscopy has been performed. Mediastinos-
copy does not detect N1 nodes in comparison with node
sampling at thoracotomy. Although the estimate of sensitivity
for PET-CT when compared with mediastinoscopy alone was
100% (95% CI, 76–100%), this likely represents an overes-
timate in light of the relatively small number of lymph nodes
sampled and the prevalence of disease.
The current analysis is based on patients assessed
prospectively in one arm of a randomized controlled trial.
The relatively few participating PET-CT centers allowed for
a high level of adherence to quality control measures, and all
of the thoracic surgeons were experienced in the conduct of
clinical trials. As the patient, rather than the lymph node, is
the more clinically appropriate unit of analysis, we chose to
use patient-level data as the unit of our analyses. An impor-
tant strength of our study was that all but two patients who
were candidates for surgery had mediastinal nodes sampled
systematically at thoracotomy, whether or not they had been
sampled previously by mediastinoscopy.
Although the size of the PET-CT arm was larger than
three previous randomized controlled trials,9,10,12 the sample
size and the number of lymph nodes sampled per region were
still relatively limited, especially when imaging was com-
pared with mediastinoscopy. The high prevalence of clinical
stage I disease at baseline (80%) within the PET-CT cohort is
not typical of the usual stage distribution at diagnosis for
NSCLC and could impact the generalizability of our results.24
In our study, PET-CT erroneously staged 29 of 149
patients. Of these, 14 could be considered as clinically rele-
vant: 8 of 11 who were overstaged and 6 of the 18 patients
who were understaged. Importantly, based on PET-CT alone,
eight patients would have been denied potentially curative
surgery. If the results of our study were to be extrapolated to
the incidence and stage-specific prevalence data available
through the SEER database, noninvasive staging by PET-CT
alone could result in inaccurate staging in 12,844 of the
NSCLC patients diagnosed in the United States in 2010.1,3,24
Of these, incorrect staging would alter treatment in 6191
patients. Importantly, approximately 3500 patients in the
United States and 385 patients in Canada would be denied
potentially curative resection based on noninvasive staging
with PET-CT this year alone.2
In conclusion, a positive PET in the mediastinum must
be confirmed by biopsy in patients who are potentially oper-
able. This is true regardless of the clinical stage by CT
because, in our study, the false-positive rates (1-PPV) for
PET were 50, 20, and 29% for cN0, cN1, and cN2 patients,
respectively. A negative PET in the mediastinum is reliable
for cN0 patients (false-negative rate [1-NPV] of 3%). How-
ever, a negative PET in the mediastinum must be confirmed
by biopsy for cN1 and cN2 patients by CT as the false
negative rates (1-NPV) of PET in our study were 22 and 25%,
respectively.
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